Highly expressed • Durable • Antibiotic free • Proven
NTC’s antibiotic free Nanoplasmids™ are easily substituted for conventional plasmids, minicircles, doggy bones, etc., for use with all major therapeutic vector groups. The Nanoplasmid™ backbone has profound and unexpected beneficial effects on performance (expression levels and duration). The Nanoplasmid™ is now available for use in: Lenti vectors, CAR-T cell vectors, AAV, transposons, etc. NTC’s RNA-OUT sucrose selection is a regulatory agency preferred antibiotic-free backbone, and has already been approved and used successfully in a number of first-in-human clinical trials.
Retrofitting a pVAX plasmid (1) with RNA-OUT (antibiotic free) selectable marker (2), or (3) with Nanoplasmid™ (RNA-OUT plus R6K ori), or (4)with Nanoplasmid™ plus BGH poly(A), dramatically improves expression, up to ten (or more) fold. Scale: Fluorescence Units (FU).
pVAX Nanoplasmid™ Retrofits
|No.||Vector||Intron||ORI-Marker||A549 EGFP-FU||+/- SD||HEK EGFP-FU||+/- SD|
In summary, the Nanoplasmid (RNA-OUT selectable marker plus R6K origin) replaces antibiotics with sucrose selection, and replaces the promiscuous pUC origin with the host-restricted R6K one. It is:
Smaller in size (452bp) than conventional marker/ORIs, therefore increasing potency and decreasing material cost
Easily swappable into most types of viral and nonviral vectors
- HyperGRO compatible for high yield Nanoplasmid manufacturing
- Purified using conventional plasmid DNA downstream purification processes, and does not require post-production modification (such as minicircles), and is therefore the ideal vector for products that are destined for clinical use
Dramatically improves expression levels and duration of expression compared to Kanamycin vectors
Nanoplasmid™ is an ideal vector: Used by over 50 gene therapy companies worldwide
Small Backbone • Fast • Economical • Antibiotic-Free • Scalable